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Low adherent cancer cell 
subpopulations are enriched 
in tumorigenic and metastatic 
epithelial-to-mesenchymal 
transition-induced cancer stem-like 
cells
Cynthia Morata-Tarifa1,2, Gema Jiménez1,2,3, María A. García1,2,4, José M. Entrena5,6, 
Carmen Griñán-Lisón1,2, Margarita Aguilera2,7, Manuel Picon-Ruiz1,2,8 & Juan A. Marchal1,2,3
Cancer stem cells are responsible for tumor progression, metastasis, therapy resistance and cancer 
recurrence, doing their identification and isolation of special relevance. Here we show that low adherent 
breast and colon cancer cells subpopulations have stem-like properties. Our results demonstrate that 
trypsin-sensitive (TS) breast and colon cancer cells subpopulations show increased ALDH activity, 
higher ability to exclude Hoechst 33342, enlarged proportion of cells with a cancer stem-like cell 
phenotype and are enriched in sphere- and colony-forming cells in vitro. Further studies in MDA-MB-231 
breast cancer cells reveal that TS subpopulation expresses higher levels of SLUG, SNAIL, VIMENTIN 
and N-CADHERIN while show a lack of expression of E-CADHERIN and CLAUDIN, being this profile 
characteristic of the epithelial-to-mesenchymal transition (EMT). The TS subpopulation shows CXCL10, 
BMI-1 and OCT4 upregulation, differing also in the expression of several miRNAs involved in EMT and/or 
cell self-renewal such as miR-34a-5p, miR-34c-5p, miR-21-5p, miR-93-5p and miR-100-5p. Furthermore, 
in vivo studies in immunocompromised mice demonstrate that MDA-MB-231 TS cells form more and 
bigger xenograft tumors with shorter latency and have higher metastatic potential. In conclusion, 
this work presents a new, non-aggressive, easy, inexpensive and reproducible methodology to isolate 
prospectively cancer stem-like cells for subsequent biological and preclinical studies.
The cancer stem cell (CSC) model posits that tumors are maintained by a subpopulation of cells that self-renew 
and yield heterogeneous progeny with reduced proliferative potential1,2. Different molecular mechanisms activated 
in normal stem cells are also involved in CSC self-renewal, including the expression of certain embryonic stem 
cells-transcription factors (ES-TFs)3 or the similar regulation of several signaling pathways4,5. Additionally, short 
non-coding miRNAs are also able to modulate gene expression programs to maintain self-renewal in normal and 
CSCs6.
It is important to note that CSCs also underlie drug resistance, tumor recurrence and metastasis1,2,7. Drug resist-
ance and tumor recurrence showed by CSCs are mainly explained by the overexpression of multidrug resistance 
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(MDR) membrane proteins and the enzyme aldehyde dehydrogenase (ALDH), or their ability to maintain a 
quiescent state8. On the other hand, metastasis is one of the most crucial steps in cancer progression and the main 
cause of mortality1. During local invasion and distant metastasis, the associated cancer cells typically develop 
alterations in their shape as well as in their attachment to other cells and to the extracellular matrix9. Metastatic 
cancer cells are characterized for suffering an epithelial-to-mesenchymal transition (EMT), a process by which 
cancer cells lose their attachment to the epithelial niche and acquire a mesenchymal phenotype10. These cells then 
are transported through the vasculature and are disseminated to anatomically distant organ sites where are able 
to establish new neoplastic growths11,12.
The relevance of this cancer cell subpopulation has yield to develop methodologies for their identification and 
isolation. Breast CSCs are characterized by the phenotype CD44+/CD24low/− 13,14, while the expression of the cell 
surface proteins CD133, CD44 and/or CD326 is related with colon CSCs properties15–17. Other CSCs characteris-
tics that have been extensively used for their identification and isolation are their high ALDH activity and ability 
to exclude Hoechst 33342, which is used to determine the side population (SP) phenotype1,18–21. However, the 
isolation of CSCs based on all of these properties requires the fluorescence-activated cell sorting (FACS) method, 
an expensive and aggressive technique.
As it has been reported previously, cancer cells that undergo EMT acquire characteristics of CSCs22,23. On the 
other hand, it is known that during EMT process cells lose their adhesion ability with adjacent epithelial cells9. This 
property has been extensively used to remove mesenchymal cells from primary epithelial cell cultures following 
the protocol known as “differential trypsinization” developed by Owens et al. in 197424. Here we report that the 
application of this technique in cancer cell cultures shows that cells selected by differential trypsinization differ in 
phenotypical and functional CSCs properties, including ALDH activity, SP proportion, xenograft tumor formation 
ability and metastatic potential, among others. As expected, trypsin-sensitive (TS) cancer cells subpopulations 
show increased CSCs properties when compared with the total population (TP) and/or the trypsin-resistant (TR) 
subpopulation.
Materials and Methods
Cell lines and cell culture. Breast (MCF7 and MDA-MB-231) and colon (HT-29 and T84) cancer cell lines 
were obtained from American Type Culture Collection (ATCC) and cultured following ATCC recommendations.
Differential trypsinization. Cells at 60–80% of confluence were slowly washed with phosphate buffered 
saline (PBS) without directly flow falls on the cells. Then, 0.05% trypsin was added and incubated 2 minutes 
at 37 °C. Detached cells were collected in centrifuge tubes and were named as Trypsin-Sensitive 1 (TS1). The 
remaining attached cells were washed twice and, then, 0.25% trypsin was added. These cells were named as 
Trypsin-Resistant 1 (TR1). On the other hand, TS1 cells were again plated for 24 hours. After that, 0.05% trypsin 
was added and incubated for 2 minutes at 37 °C. These detached cells were named as Trypsin-Sensitive 2 (TS2) 
(Fig. 1A).
In order to separate more strictly cells with stem-like and no stem-like properties, cells were grown until 60–80% 
of confluence and washed slowly with PBS. After obtaining the TS1 subpopulation, remaining cells attached to the 
dishes were washed twice with PBS and incubated with 0.05% trypsin for 4 minutes at 37 °C. Cells detached from 
this trypsinization were discarded. Dishes with remaining trypsin-resistant cells were named as TR2 (Fig. 1B). 
Total population (TP) was used as control cells.
Flow cytometry analyses. ALDEFLUOR assays (Stem Cell Technologies) to detect ALDH1 activity 
were performed according to manufacturer’s instructions. Diethylaminobenzaldehyde (DEAB) was used as an 
ALDH1 inhibitor to set ALDH1 gates. Cell surface levels were determined with anti-human antibodies CD44-PE, 
CD24-APC, CD133-APC, CD326-FITC, CK18-FITC and CK20-FITC (Miltenyi Biotec). All samples were ana-
lyzed on a FACS CANTO II (BD Biosciences) using the FACS DIVA software.
Side population assays. Hoechst 33342 exclusion (Side Population) assays were carried out as previously 
described21,25.
Sphere-forming assay. 3 × 103 cells were washed with PBS and resuspended in spheres culture medium 
(DMEM:F12, 1% penicilin/streptomycin, B27, 10 μ g/mL ITS, 1 μ g/mL Hydrocortisone, 4 ng/mL Heparin, 10 ng/mL 
EGF, 20 ng/mL FGF) in ultra-low adherence 24-well plates (Corning). Spheres > 75 μ M diameter were counted 
after 6 days by light microscopy.
For the secondary sphere-forming assay, cells from primary spheres were collected by centrifugation, then 
dissociated with trypsin-EDTA and mechanically disrupted with a pipette. 103 single cells were plated and resus-
pended in spheres culture medium in ultra-low adherence 24-well plates. Spheres > 75 μ M diameter were counted 
after 6 days by light microscopy.
Soft agar assay. 104 cells were seeded in 0.4% cell agar base layer, which was on top of 0.8% base agar layer in 
6-well culture plates. Cells were then incubated for a further 21 days at 37 °C and 5% CO2. Cell colony formation 
was then examined under a light microscope after staining with 0.01% Crystal Violet (Sigma-Aldrich).
qRT-PCR. Total RNA extraction and qRT-PCR assays were done following standard protocols. See 
Supplementary Material and Methods for more details. Primer sequences are listed in Supplementary Table 1.
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Proliferation assay. Different subpopulations (TP, TS1 and TR2) were seeded in 24-well plates in medium 
supplemented with 10% FBS for 6 days. Cells were incubated with MTT every two days and the fluorescence was 
measured at 570 nm.
Lentivirus transfections. 293T cells were co-transfected with a lentiviral vector encoding for the firefly 
luciferase and the red fluorescent protein td-Tomato (L2T)26, a packaging vector (psPAX2) and an envelope vector 
(pCMV-VSVG) using lipofectamine transfection reagent (Life Technologies). Viral particles produced from 293T 
cells were collected and used to infect MDA-MB-231 cells. Briefly, supernatant recovered after 48h from 293T 
transfected cells was filtered by a 0.45 μ m pore membrane and added to MDA-MB-231 plated cells supplemented 
with 4 μ g/mL polybrene (Sigma-Aldrich). After viral infection, td-Tomato+ cells were selected for stable integra-
tion of the transfects by FACS.
Mouse models. Tumor-initiation experiments and experimental lung metastasis assays are detailed in 
Supplementary Materials and Methods. All animal studies were performed according to protocols reviewed and 
approved by the Institutional Animal Care and Use Committee at the University of Granada.
Figure 1. Differential trypsinization protocols. (A) Isolation of TS1, TS2 and TR1 subpopulations, used 
for Aldefluor assays, Hoechst 33342, surface markers, spheres and colonies formation ability. (B) Improved 
protocol to isolate highly attached cells (TR2) used for Aldefluor, qRT-PCR and in vivo assays. Red balls 
represent cells with higher CSC-like properties and green balls cells with a non CSC-like phenotype.
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Histological and immunological analysis. Described in detail in Supplementary Materials and Methods.
Statistical analysis. All graphed data are presented as mean ± SD from at least three experiments. 
two-tailed Student’s t-tests and two-way ANOVA were used to determine statistical differences for in vitro and in 
vivo experiments respectively. P-values < 0.05 were considered statistically significant in all cases.
Results
Trypsin-sensitive subpopulation displays CSC-like phenotypic properties. To test whether TS 
subpopulations are enriched in CSC-like properties, we determined the ALDH activity, the rate of SP and spe-
cific breast and colon CSC-related cell surface markers (Fig. 2). Regarding to ALDH activity, both TS1 and TS2 
subpopulations presented a significantly higher proportion of ALDH positive cells than TP. In contrast, TR1 sub-
population displayed a lesser ALDH activity, although this change was not significant when compared to the TP 
(Fig. 2A, Supplementary Fig. S1A and Supplementary Table 2).
Accordingly, the rate of SP in TS subpopulations was significantly higher than in both TP and TR1 cells for all 
cell lines tested. Thus, TS1 cells showed values ranged from 48.6% up to 70.5% and TS2 from 82.3% up to 89.9%. 
However, TP cells displayed percentages comprising between 3.9% and 13.2% (Fig. 2B, Supplementary Fig. S1B 
and Supplementary Table 3).
Moreover, we determined CD44/CD24 expression for breast and CD44/CD133/CD326 expression for colon 
cancer cell lines to study the proportion of cancer cells with a CSC phenotype in the different subpopulations. 
Flow cytometry analysis indicated that in the MCF7 cell line, TS1 and TS2 subpopulations showed a significantly 
higher CD44+/CD24− proportion than TP and TR1 (Fig. 2C). However, no significant differences were found 
for these markers in the different subpopulations of the MDA-MB-231 breast cancer cell line, probably due to 
the high proportion of cells with this phenotype in the TP (Fig. 2D). In HT-29 colon cancer cells, the expression 
of CD44+/CD133+/CD326+ was significantly higher for TS1 and TS2 in comparison to TR1, although only TS2 
showed a significant increase in the proportion of cells with this phenotype when compared to the TP (Fig. 2E). 
It is important to note that HT-29 cells showed two different subpopulations based on CD326 expression, and 
that CD326high and CD326low HT-29 cells were separated prospectively by differential trypsinization, being the TS 
subpopulation composed for CD326high cells (Supplementary Fig. S1C). In regards to T84 colon cancer cells, TS1 
and TS2 showed a higher enrichment in cells with a CD44+/CD326+ phenotype, even when their expression was 
studied together or separate (Fig. 2F). Differences in the expression of CD133 were not significant; however, this 
cell surface marker was more expressed in TS subpopulations (Supplementary Fig. S1D).
Trypsin-sensitive subpopulation possesses higher self-renewal ability and clonogenicity. We 
next tested in vitro functional characteristics of these cell subpopulations isolated by differential trypsinization. 
We studied the anchorage-independent growth of TS and TR subpopulations under free-serum conditions to 
determine their self-renewal ability; and also their clonogenic capacity by colony-formation assay in soft agar. As 
it is shown in Fig. 3A,B, tumorspheres were formed more efficiently from TS1 and TS2 than TR1 and TP cells in 
all cell lines; therefore TS subpopulations have a higher capacity of self-renewal. Moreover, TR1 subpopulation 
formed significantly less spheres than TP for MCF7, MDA-MB-231 and T84 (Fig. 3A,B).
We also performed a secondary sphere-formation assay by dissociating primary spheres formed by TS1, TR1 
and TP cells, as indicated in the Materials and Methods section. As it is shown in Fig. 3C for the breast cancer 
MDA-MB-231 and colon cancer T84 cell lines, the number of cells with the ability to form secondary spheres was 
higher in primary spheres formed by the TS1 subpopulation, while those formed by TR1 were poorly enriched in 
sphere-forming cells. In addition, TS subpopulations showed a significant higher capacity to form colonies in soft 
agar than TP for all cell lines studied (Fig. 3D). These data are in concordance with our previous results obtained 
from the primary sphere formation assay and support our prior conclusion about the higher self-renewal ability 
of the TS subpopulation.
All together, these results indicate that cells isolated by differential trypsinization differ in their enrichment 
in cells with functional CSC-like properties. Furthermore, the rate of these cells in the subpopulations isolated is 
well maintained when cells are cultured in suspension in FBS-free media.
Isolation of cancer cells with stem- and no stem-like properties based on their adhesion capacity. 
As we shown above, we obtained a cell subpopulation enriched for CSCs features based in their lower adhesion 
capacity to the cell culture surface. The amount of cells detached after the first trypsinization was very low and 
the rest of attached cells was very similar to the total population. For this reason, to demonstrate that it is possible 
to separate CSCs and cancer cells no stem based on their sensitivity to trypsin digestion, we developed another 
protocol. After the first trypsinization we recovered the TS1 subpopulation and remaining attached cells were 
trypsinized again with the same trypsin dilution indicated above, but in this case for 4 minutes. Cells that were 
detached by this last trypsinization were discarded and cells still attached were recovered and named as TR2, as 
described in the Material and Methods section (Fig. 1B). As it is shown in Fig. 4A and Supplementary Fig. S2, 
TP and subpopulations TS1 and TR2 differed in ALDH activity. In concrete, TS1 subpopulation was enriched in 
cells with a high ALDH activity, with purity higher than 90%, and TR2 showed a lack of ALDH activity in both 
MDA-MB-231 and MCF7 (Fig. 4A and Supplementary Fig. S2). As it is shown the purity of ALDH+ cells obtained 
by differential trypsinization from MCF7 cells was similar to the enrichment obtained by FACS (Supplementary 
Fig. S2).
On the other hand, we also studied the expression levels of both the luminal cytokeratin 18 and the intesti-
nal epithelium differentiation cytokeratin 20 for breast and colon cancer cells, respectively, after differentiation 
of TS1 cells in media containing FBS for 7 days when grown attached to the cell culture surface. As it is shown 
in Supplementary Fig. S3, TS1 cells cultured under these conditions recovered the expression levels of these 
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Figure 2. Phenotypic properties of breast and colon cancer cell subpopulations isolated by differential 
tripsinization. Percentage of ALDH+ (A) and SP (B) cells determined in subpopulations of MCF7, 
MDA-MB-231, HT-29 and T84 cancer cell lines. (C,D) Percentage of CD44+/CD24− cells in TR1, TP, TS1 
and TS2 isolated from MCF7 (C) and MDA-MB-231 (D) breast cancer cells measured by flow cytometry. (E) 
Co-expression of CD44, CD133 and CD326 in HT-29 cells isolated by differential trypsinization and in the 
TP. (F) Flow cytometry for CD44 and CD326 expression, alone or together, in T84 cells. Data are graphed as 
mean ± SD from at least two different experiments carried-out by triplicates (**P < 0.01; *P < 0.05). See also 
Supplementary Fig. S1.
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cytokeratins at similar values than those observed in the TP. These results are an indicator of the ability of the TS1 
cells to recapitulate the heterogeneity of the parental cell line.
Trypsin-sensitive subpopulation expresses higher levels of EMT- and pluripotency- associated 
genes. The enrichment of cancer cells with stem cell-like properties in cells which show low adherence to 
plastic surface may be due to an EMT process, which is associated with metastasis. To understand the molecular 
changes underlying the different characteristics of these cell subpopulations, we analyzed the expression of genes 
related with the EMT process and/or pluripotency on MDA-MB-231 cells.
qRT-PCR studies demonstrated that all genes assayed were expressed differentially in the TS1 and the TR2 
cell subpopulations. SNAIL, SLUG, VIMENTIN, N-CADHERIN, CXCL10, OCT4 and BMI1 were overexpressed 
in the TS1 subpopulation when compared to the TP, and underexpressed in the TR2 subpopulation (Fig. 4B). In 
Figure 3. Tumorsphere- and colony-forming ability of breast and colon cancer cell subpopulations isolated 
by differential trypsinization. (A) Representative images of mammospheres formed from different MCF7 
subpopulations. (B) Number of spheres formed by different subpopulations of each cell line. (C) Secondary 
sphere formation assay performed in MDA-MB-231 and T84 cells selected by differential trypsinization and 
compared to the TP. Data shown as mean ± SD (**P < 0.01; *P < 0.05). (D) Number of colonies formed by TP 
and TS1 of each cell line. Data are represented as mean ± SD (**P < 0.01; *P < 0.05).
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Figure 4. ALDH activity, mRNA and miRNA expression in enriched subpopulations of MDA-MB-231 cells 
isolated by their different adhesion capacity. (A) Aldefluor assay performed in TR2, TP and TS1 MDA-MB-231 
cells. See also Supplementary Fig. S2. (B) qRT-PCR analysis for the expression of CSCs and EMT-related genes 
in different subpopulations of MDA-MB-231 cells. Data are normalized to 1 for TP using GAPDH as internal 
control, and graphed as mean ± SEM (n = 3) (**P < 0,01; *P < 0,05). (C) Differential expression of miRNAs 
related to CSC phenotype and/or EMT in MDA-MB-231 cells isolated by differential trypsinization. Data are 
normalized to 1 for TP using miR-24c-3p as internal control, and graphed as mean ± SEM (n = 3) (**P < 0.01; 
*P < 0.05).
www.nature.com/scientificreports/
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contrast, expression levels of CLAUDIN1 and E-CADHERIN were higher in TR2 cells and much lower in the TS1 
subpopulation (Fig. 4B).
On the other hand, the expression patterns of several miRNAs related with EMT and/or pluripotency also differ 
between these two cell subpopulations isolated by differential trypsinization. The TR2 subpopulation showed a 
significant increase in the expression levels of miR-93-5p, miR-34a-5p, miR-100-5p and miR-34c-5p (Fig. 4C). 
However, all of these miRNAs were downregulated in the TS1 subpopulation when compared to the TP, although 
not all of them were statistically significant (Fig. 4C). In contrast, the expression of miR-21-5p was higher in TS1 
and lower in TR2 cells when compared to the TP (Fig. 4C).
Moreover, the proliferation assay demonstrated that both TR2 and TP subpopulations grow faster that TS1 for 
all tumor cell lines (Fig. 5), showing that the TS1  subpopulation has a lower proliferation rate in vitro.
Trypsin-sensitive subpopulation is enriched in tumor-initiating cells. To confirm the results 
observed in vitro, TS1 and TR2 subpopulations were isolated from MDA-MB-231 cells, injected subcutaneously 
in NSG mice and compared with the TP in a limiting dilution in vivo assay. The overall survival of mice injected 
with TS1 cells was lower than for the other groups (Fig. 6A). When 5 × 103 TS1, TP or TR2 cells were injected, 
the overall survival of mice was 63 and 77 days, for TS1 and TP respectively, while 2 out of 6 mice injected with 
the TR2 subpopulation were still alive at day 81, the end-point of the experiment (Fig. 6A). Furthermore, tumor 
volume was higher after injection of TS1 cells, while tumors formed by TR2 cells were smaller (Fig. 6B), being 
these results not explained by a global mitogenic effect since TR2 cells have higher proliferation rate than TS1 cells 
(Fig. 5). Similar results were observed when 1.5 × 104 cells were injected, however the overall survival was shorter 
and the tumor size bigger for all groups, as it was expected (Fig. 6A,B). All together, these data demonstrate that 
TS cells are enriched in CSCs with a high tumor-initiating capacity while the TR subpopulation is composed 
mainly by non CSC-like cells.
Trypsin-sensitive subpopulation generates more metastasis than trypsin-resistant subpopula-
tion after tail vein injection. To further demonstrate the higher aggressiveness of the TS subpopulation, 
we compared the metastatic ability of both cell subpopulations isolated by differential trypsinization (TS1 and 
TR2) with the TP using MDA-MB-231 L2T cells. When 2.5 × 105 TS1 cells were injected into the tail vein of NSG 
mice, 5 of 6 animals developed lung metastasis, however only 4 and 2 of 6 animals developed metastasis when 
TP or TR2 cells, respectively, were injected (IVIS images from week 3 are shown in Fig. 7A). In addition, the TS1 
Figure 5. Proliferation assay. Proliferation curves of TS1, TR2 and TP cells cultured for 6 days in media 
containing FBS, and measured using MTT every 2 days in cultures seeded with an equal number of cells at day 0. 
Data are represented as absorbance at 570 nm and shown as mean ± SD (**P < 0.01; *P < 0.05).
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subpopulation, that showed the lowest proliferation rate in vitro (Fig. 5), caused a more rapid increase in tumor 
bioluminescence, demonstrating their higher metastatic ability (Fig. 7A). After 4 weeks, animals were sacrificed 
and lungs harvested for further analysis (Fig. 7B). Lungs from mice injected with TS1 cells showed more pulmo-
nary metastatic nodules than these from TP or TR2 cells (representative images, Fig. 7C). Furthermore, histolog-
ical and immunohistochemical analysis of lungs demonstrated that metastatic nodules formed by TS1 cells were 
bigger when compared to the TP, and smaller when TR2 cells were injected (Fig. 7D,E), being these differences in 
size independent of a global mitogenic effect (Fig. 5). This further demonstrates the higher metastatic ability of 
the TS subpopulation and that the TR subpopulation is composed by non CSC-like cells.
Discussion
In this work, we demonstrate that cultured cancer cells possess low adherent cancer cell subpopulations with 
stemness properties. Therefore, differential trypsinization, an extended methodology for the establishment of 
primary epithelial cell cultures24,27, can be applied to isolate breast and colon cancer cells with CSCs properties 
in vitro and in vivo, and likewise for other cancer types with an epithelial origin. In this work, we demonstrate 
that two distinct subpopulations of cancer cells can be isolated by this protocol: i) a subpopulation with CSCs 
properties and lower adherence ability (TS subpopulation); ii) and a highly adherent subpopulation enriched in 
non CSC-like cells (TR subpopulations).
Breast and colon cancer TS subpopulation is enriched in cells with high ALDH activity, and greater SP rate, 
being these characteristics associated with CSCs properties. The isolation of a subpopulation with high ALDH activ-
ity has been demonstrated to show higher tumorigenic potential in both breast and colon cancers18,20. Regarding 
to Hoechst 33342 dye efflux, different studies have shown that the SP phenotype is enriched in cancer stem-like 
cells in different tumors, including breast and colon cancers19,21. Moreover, the ability to exclude Hoechst 33342 
is associated with an upregulation of ATP-binding cassette transporters that confer multidrug resistance, a char-
acteristic of CSCs28.
However, the characterization of CSCs by the expression of specific cell surface markers is the most extended 
method to identify and isolate this cancer cell subpopulation. We have demonstrated that MCF7 breast cancer cells 
from the TS subpopulation are enriched in cells with a CD44+/CD24− phenotype, which is characteristic of breast 
Figure 6. Overall survival and subcutaneous xenograft tumor formation (A) Kaplan-Meier curve for overall 
survival of NSG mice injected with 5 × 103 cells (left) and 1.5 × 104 cells (right) from TS1, TR2 or TP. (B) Tumor 
volume (mm3) of subcutaneous xenograft tumors formed by 5 × 103 and 1.5 × 104 cells from TS1, TR2 and TP in 
NSG mice. Data are shown as mean ± SD (**P < 0.01; *P < 0.05).
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CSCs13. On the other hand, HT-29 and T84 TS colon cancer cells are enriched in CD44+, CD133+ and/or CD326+ 
cells. Colon CSCs were firstly identified based on the expression of CD133, being determined that the ability to 
develop tumors in immunodeficient NOD/SCID mice was restricted to CD133+ cells15,16. In a latter study, Dalerba 
et al. demonstrated that the ability to engraft in immunodeficient mice was restricted to a minority subpopulation 
CD326high/CD44+. Furthermore, tumors originated from CD326high/CD44+ cells maintained a differentiated 
Figure 7. Experimental lung metastasis assay. (A) IVIS images of lung metastasis formed after tail vein 
injection of TP, TR2 and TS1 MDA-MB-231 L2T cells (up). Measure of photon flux is graphed as mean ± SEM 
(down). (B) Fluorescence of metastatic lungs ex vivo. (C) Representative optical images of lung metastasis 
for a healthy mice (control) and lungs extracted from NSG mice injected with different subpopulations of 
MDA-MB-231 cells obtained by differential trypsinization. (D,E) Histological (D) and immunohistochemical 
(E) images of lungs obtained from healthy mice (control) and mice injected with TR2, TP and TS1 cells (left to 
right).
www.nature.com/scientificreports/
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phenotype and reproduced the full morphologic and phenotypic heterogeneity of their parental lesions17. Regarding 
to MDA-MB-231 TS cells, we did not see a significant increase in the CD44+/CD24− subpopulation, however the 
percentage in all groups was very high, around 80%, which is in concordance with the highly invasive/metastatic 
skills of this triple negative breast cancer cell line29.
Breast and colon cancer cells isolated by differential trypsinization also differ in their self-renewal ability. CSC 
self-renewal can be assayed in vitro by tumor spheres and holoclone colonies formation assays30. The TS subpopu-
lation obtained from both breast and colon cancer cell lines generated more colonies in soft agar and spheres in low 
attachment plates under serum deprivation. It has been demonstrated that colon CSCs enriched in CD133+ cells 
form more colonies in soft agar used as indicator of their higher tumor-initiating ability31. In addition, it has been 
shown that MDA-MB-231 breast cancer cells enriched in cancer-initiating stem cells have higher colony-formation 
ability32. On the other hand, CSCs have the ability to form spheres in low-attachment culture surfaces under free 
serum conditions and this kind of culture conditions increases the percentage of cells with a CSC phenotype 
based on surface markers expression25,33. In contrast, the number of colonies and spheres formed from TR cells 
was significantly lower than in the TP, indicating the lower self-renewal ability and therefore, the non CSC-like 
properties of this cancer cell subpopulation selected by a higher adhesion capability to the cell culture surface.
All these in vitro studies for phenotypical and functional properties of CSCs were notably increased in the TS 
subpopulations for all cell lines, except for CD44+/CD24− expression in MDA-MB-231 breast cancer cells that is 
basally high in TP cells. For this reason, we selected this cell line to perform further studies. qRT-PCR analysis of 
different mRNA and miRNA related with EMT, self-renewal and/or aggressiveness demonstrated differences in 
their expression between TR and TS subpopulations. The gene profile of MDA-MB-231 TS cells was more associ-
ated with a mesenchymal phenotype while the TR subpopulation was more related with an epithelial phenotype. 
During the EMT process, cancer cells lose their attachment to the epithelial niche and acquire a mesenchymal 
phenotype which is characteristic of metastatic cancer cells34. Moreover, the triple-negative MDA-MB 231 breast 
cancer cell line, which overexpresses EGFR35, has potent and reproducible migratory responses36. MDA-MB-231 
TS cells showed a lack of expression of E-CADHERIN and CLAUDIN. The loss by carcinoma cells of E-cadherin, 
a key cell-to-cell adhesion molecule which establish adherent junctions with adjacent epithelial cells, is the best 
characterized alteration during the EMT process9,34. In regard to claudin expression, a phenotype claudin-low is 
associated with enrichment for EMT markers, immune response genes, cancer stem cell-like features and poor out-
come in breast cancer37. In addition, the TS subpopulation also shows a higher expression of several transcription 
factors that modulates the EMT, such as SNAIL or SLUG, and other mesenchymal markers including N-CADHERIN 
and VIMENTIN38. In contrast, the expression of these genes was contrary regulated in MDA-MB-231 TR cells, 
indicating their more epithelial features. In fact, we have recently demonstrated important role of Vimentin/Slug 
EMT markers in tumor growth of primary breast cancer patients and in circulating tumor cells (CTCs) EGFR+ 
from cytokeratin negative non-metastatic breast cancer patients39.
Certain ES-TFs, such as Oct4, Sox2 and Nanog, which are master regulators of ES self-renewal and pluripotency, 
are also upregulated in CSCs40. OCT4 expression was measured in MDA-MB-231 cells, demonstrating that it is 
overexpressed in the TS subpopulation. Interestingly, a recent study showed that Oct4 is associated with poor prog-
nosis and that positively regulates the EMT process, contributing to breast cancer metastasis38. Furthermore, CSCs 
share similarities with normal stem cells in the regulation of the Wnt, Notch and Hedgehog signaling pathways, 
and the expression of several genes of the polycomb family, including BMI-1, or the HOX family among others 
which are involved in stem cells self-renewal4. BMI-1, which is overexpressed in TS cells, has been also related with 
the EMT process and drug resistance41. Moreover, CXCL10 is expressed in basal tumors as compared with ER+ 
tumors, being associated with a higher tumor grade and a poor prognosis of breast cancer42.
On the other hand, miRNAs play critical regulatory roles in a wide range of biologic and pathologic processes, 
and miRNA expression profiling reveals substantial differences between cancer and normal tissue, and among dif-
ferent cancer types43. We studied the expression patterns of different miRNAs that have been previously shown to be 
related with CSCs properties, EMT, metastasis and poor outcome. For example, the TR subpopulation overexpresses 
miR-93, which inhibits cell proliferation, the capacity to form colonies44 and promotes mesenchymal-to-epithelial 
transition (MET)45. miR-34a-5p and miR-34c-5p are downregulated in TS cells and upregulated in the TR sub-
population. miR-34 family are reportedly as tumor-suppressor miRNAs implicated in reduced CSC properties 
and increased sensitivity to drug treatment by directly targeting NOTCH146. miR-100 is also upregulated in the TR 
subpopulation, and its expression levels relate to the cellular differentiation state, with lowest expression in cells 
displaying stem cell markers47. In addition, the expression of miR-21, a well known miRNA which is dysregulated 
in several types of cancer and plays a key role in carcinogenesis, recurrence and metastasis48, is increased in the 
TS subpopulation and decreased in TR cells.
All together, these data demonstrate that differential trypsinization of breast and colon cancer cell cultures 
allows the isolation of two subpopulations (TR and TS) that differ in their CSC-like cells properties. TS cells show 
increased ALDH activity, SP proportion and CSC-like phenotype. This subpopulation is enriched in cells that have 
followed an EMT process and possess high self-renewal ability. Moreover, TS cells show higher tumorsphere- and 
colony-formation ability in vitro; and tumorigenic and metastatic potential in vivo. In contrast, the TR subpop-
ulation is mainly composed by non CSC-like cells with a lower tumorigenic capacity both in vitro and in vivo. In 
a previous study carried-out by Walia and Elbe, it was shown that the TS subpopulation, obtained by differential 
trypsinization from transformed human mammary epithelial cells, was enriched in stem cell properties49. In a more 
recent study, this methodology was used to isolate a subpopulation of cells with a mesenchymal phenotype from an 
oncogenic transformed human mammary epithelial cell line50. However, these studies were limited to determine 
EMT markers expression, mammosphere-forming ability, drug resistance and CD44/CD24 expression, and were 
carried-out in a well differentiated oncogenic transformed human mammary epithelial cell line.
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Conclusion
In summary, our results evidence that cultured cancer cells possess low adherent cell subpopulations with stem-
ness properties and with high tumorigenic and metastatic abilities. We show for the first time that differential 
trypsinization, a new, non-aggressive, easy, inexpensive and reproducible methodology to isolate prospectively 
breast and colon cancer stem-like cells for subsequent biological studies, high throughput screening therapeutic 
strategies targeting CSCs and preclinical assays.
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